- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.10. | FDA accepts priority review for Orca Bio's hematological malignancy therapy | ||
| 06.10. | FDA fast-tracks Alto Neuroscience's ALTO-101 for CIAS treatment | ||
| 01.10. | FDA approves Novartis' Rhapsido for CSU treatment | ||
| 30.09. | BioLineRx partners with Hemispherian to advance brain cancer therapy | ||
| 29.09. | AbbVie files NDA with FDA for tavapadon to treat Parkinson's disease | ||
| 26.09. | Lilly secures EC approval for Kisunla to treat Alzheimer's disease | ||
| 25.09. | Sandoz launches generic iron sucrose injection in US market | ||
| 24.09. | Leqembi approved in Australia to treat early Alzheimer's | ||
| 23.09. | Avenzo Therapeutics secures $60m in series B funding for oncology therapies | ||
| 22.09. | J&J's Tremfya gets FDA approval for SC induction in active UC | ||
| 19.09. | Biogen to acquire Alcyone Therapeutics for $85m | ||
| 18.09. | Deciphera's Romvimza secures EC nod for TGCT treatment | ||
| 17.09. | Dualitas secures $65m for bispecific antibody pipeline | ||
| 16.09. | Argo Biopharma secures NMPA clearance for Phase II PNH trial | ||
| 15.09. | YolTech Therapeutics raises approximately $45m via Series B financing | ||
| 12.09. | Dewpoint Therapeutics secures funding for DPTX3186 development | ||
| 11.09. | Odyssey Therapeutics raises $213m via Series D | ||
| 10.09. | FDA grants breakthrough therapy status to Ionis ION582 to treat Angelman syndrome | ||
| 09.09. | Novonesis and Novo Nordisk collaborate on gut microbiome research initiative | ||
| 08.09. | Takeda receives FDA approval for Vonvendi sBLA | ||
| 05.09. | FDA grants breakthrough therapy status to Eli Lilly's olomorasib | ||
| 04.09. | Andelyn and Tern partner for gene therapy to treat CLN2 Batten disease | ||
| 03.09. | Polpharma Biologics signs biosimilars licensing deals with MS Pharma | ||
| 02.09. | OMass signs deal with Genentech for IBD small molecules | ||
| 01.09. | FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .